Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison
Written by Elyte Peptides Research Team
How the three best-known incretin peptides differ — semaglutide (GLP-1), tirzepatide (GIP/GLP-1), and retatrutide (GIP/GLP-1/glucagon) — covering receptor targets, mechanisms, half-lives, development stage, and what trials have shown.
TL;DR: Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist, hitting both the GIP and GLP-1 receptors. Retatrutide is a triple agonist that adds glucagon receptor activity on top of GIP and GLP-1 — and glucagon-receptor signaling is associated in research with increased energy expenditure and hepatic lipid oxidation, which is what sets the triple agonist apart mechanistically. All three have produced substantial body-weight reductions in study participants in their respective clinical programs; semaglutide and tirzepatide are the furthest along, while retatrutide remains in later-stage development.
Comparison Table
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Class | GLP-1 receptor agonist | Dual GIP/GLP-1 agonist (“twincretin”) | Triple agonist |
| Designation | — | — | LY3437943 |
| Approx. half-life | ~1 week (long-acting) | ~5 days | ~6 days (long-acting) |
| Development stage | Established clinical agent | Established clinical agent | Later-stage clinical investigation (Phase 3 program) |
| Notable trial program | STEP (obesity), SUSTAIN (T2D) | SURMOUNT (obesity), SURPASS (T2D) | Phase 2 reported in NEJM (Jastreboff et al., 2023); Phase 3 ongoing |
(Half-life figures are approximate values reported in the literature.)
Mechanism: Why the Receptor Count Matters
Semaglutide — single GLP-1 agonist
Semaglutide binds the GLP-1 receptor, which in research is linked to slowed gastric emptying, glucose-dependent insulin secretion, and modulation of appetite-related signaling in the central nervous system. It’s the most-studied incretin peptide and the reference point the others are measured against.
Tirzepatide — dual GIP/GLP-1 agonist
Tirzepatide adds agonism at the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is the other major incretin hormone; co-activating both receptors has been studied for effects on insulin secretion, lipid handling, and appetite that, in trials, exceeded what GLP-1 agonism alone produced. It’s sometimes called a “twincretin.”
Retatrutide — triple GIP/GLP-1/glucagon agonist
Retatrutide keeps GIP and GLP-1 and adds the glucagon receptor. Glucagon is usually thought of as a glucose-raising hormone, but at the receptor level its agonism has been associated in preclinical pharmacology (e.g., work by Coskun and colleagues on the molecule’s profile) and in human studies with increased resting energy expenditure and hepatic fat oxidation. Engineering a single peptide to balance glucagon activity against GLP-1’s glucose-lowering effect is the design challenge — and the reason the triple agonist is mechanistically distinct from anything dual or single.
What Research Has Shown
- Semaglutide: The STEP program (obesity) and SUSTAIN program (type 2 diabetes) reported substantial weight reduction and glycemic improvement in study participants over trial periods measured in months to over a year. Published in NEJM, Lancet, and JAMA among others.
- Tirzepatide: The SURMOUNT (obesity) and SURPASS (type 2 diabetes) programs reported weight reductions in study participants that were larger, on average, than those seen with GLP-1-only comparators, alongside strong glycemic effects (Jastreboff et al. and Rosenstock et al., among others, in NEJM and the Lancet).
- Retatrutide: A Phase 2 trial (Jastreboff et al., NEJM, 2023) reported dose-dependent and substantial body-weight reduction in participants over the trial period, with sub-analyses noting marked decreases in liver fat — consistent with the proposed contribution of the glucagon-receptor component. Phase 3 trials are ongoing as of 2026.
We’re describing these findings qualitatively on purpose — the headline percentages vary by dose cohort and trial, and the mechanistic story (single → dual → triple receptor coverage) is the durable point for research framing.
For the Lab Bench
All three are studied as research compounds in metabolic-pathway work. Handling is standard: store lyophilized at -20°C, reconstitute gently with bacteriostatic water along the vial wall (no shaking), refrigerate the reconstituted stock and use within ~30 days. See the reconstitution guide, the Peptide Reconstitution Calculator, and the storage & stability guide.
Elyte stocks Retatrutide (GLP3-R); browse the catalog for related incretin and metabolic research compounds, and see What Is Retatrutide? for a deeper dive on the triple agonist. Questions on COAs or handling are covered in the FAQ.
Frequently Asked Questions
What’s the core difference between these three peptides?
Receptor coverage. Semaglutide hits one receptor (GLP-1), tirzepatide hits two (GIP + GLP-1), and retatrutide hits three (GIP + GLP-1 + glucagon). More receptors engaged means a broader set of metabolic pathways activated.
Why add glucagon-receptor activity?
Glucagon-receptor agonism is associated in research with increased energy expenditure and hepatic lipid oxidation — effects absent from GLP-1-only or GIP/GLP-1 compounds. Balancing it against GLP-1’s glucose-lowering action is the engineering trick behind a triple agonist.
Which one has the most clinical data?
Semaglutide, followed by tirzepatide — both are established clinical agents with large trial programs (STEP/SUSTAIN and SURMOUNT/SURPASS respectively). Retatrutide is in later-stage development with a published Phase 2 and ongoing Phase 3 work.
Are these interchangeable in research?
No — they’re different tools. A study designed around glucagon-receptor effects needs retatrutide; one isolating GLP-1 signaling uses semaglutide. The choice follows the question.
How are they handled in the lab?
Like other lyophilized peptides: stored frozen, reconstituted gently with bacteriostatic water, refrigerated after reconstitution, used within about 30 days. See our reconstitution and storage guides.
Does Elyte sell all three?
Elyte stocks Retatrutide (GLP3-R); check the current catalog for the full set of metabolic research compounds available.
References
- Jastreboff, A.M., et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 2023.
- Jastreboff, A.M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1). New England Journal of Medicine, 2022.
- Rosenstock, J., et al. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide” (SURPASS-1). The Lancet, 2021.
- Wilding, J.P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1). New England Journal of Medicine, 2021.
- Coskun, T., et al. Preclinical pharmacology of the GIP/GLP-1/glucagon receptor triagonist (LY3437943). Cell Metabolism / related journals.
- ClinicalTrials.gov — retatrutide Phase 3 program records.
All products sold by Elyte Peptides are for laboratory research use only. Not for human consumption. Not FDA-approved.